TCR2 Therapeutics Inc. (TCRR)
Price:
1.48 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Genmab A/S
VALUE SCORE:
11
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
NEWS
5 Penny Stocks To Buy According To Analysts, Targets Up To 952%
pennystocks.com
2023-03-07 11:35:38Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
investorplace.com
2023-03-06 10:45:40TCR2 Therapeutics (NASDAQ: TCRR ) stock is jumping more than 30% in early trading on March 6 after the company agreed to merge with Adaptimmune (NASDAQ: ADAP ). Meanwhile, Adaptimmune is falling more than 15%.
TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path
seekingalpha.com
2023-02-15 06:00:01Reprioritization of pipeline sees 40% reduction of workforce with enough cash to fund pipeline into early 2025. Proof of concept established using gavo-cel for the treatment of patients with mesothelin tumors; Focus shift more towards targeting ovarian cancer patients with expected data 2nd half of 2023.
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
globenewswire.com
2023-02-08 06:45:00CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will present a company update at the SVB Securities Global Biopharma Conference (virtual) on Tuesday, February 14, 2023 at 1:00 PM ET.
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
globenewswire.com
2022-11-23 06:45:00CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29 at 2:00PM E.T.
Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)
zacks.com
2022-11-11 11:18:13TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
globenewswire.com
2022-09-27 16:15:00CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T.
TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
globenewswire.com
2022-09-26 16:15:00CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T.
TCR² Therapeutics: Betting On A Solid Reversal
seekingalpha.com
2022-08-18 06:58:46TCR² Therapeutics is a company developing two lead oncology drug candidates targeting mesothelin, a protein expressed on different tumors. Its lead candidate gavo-cel, or TC-210, has presented strong data so far in different solid tumors, including tumor regression in 94% of evaluable patients and a manageable safety profile.
TCR² Therapeutics to Participate in Two Upcoming Conferences in June
globenewswire.com
2022-06-01 06:45:00CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate at two upcoming conferences in June in New York.
TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference
globenewswire.com
2022-02-09 06:45:00CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 at 1:40PM E.T. using a virtual platform.
Here's Why TCR2 Therapeutics Inc. (TCRR) is Poised for a Turnaround After Losing 20.2% in 4 Weeks
zacks.com
2022-01-13 11:33:10TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference
globenewswire.com
2022-01-07 17:00:00CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- https://investors.tcr2.com/
TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference
globenewswire.com
2022-01-05 06:45:00CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Menzel, President and Chief Executive Officer of TCR² Therapeutics, will present an update on Company progress at the H.C. Wainwright BioConnect Conference on Monday, January 10th at 7:00AM E.T. using a virtual platform.
TCRR Stock: Why It Increased Today
pulse2.com
2021-10-20 08:23:47The stock price of TCR2 Therapeutics (Nasdaq: TCRR) increased by over 1% pre-market today. This is why it happened.
TCR² Therapeutics to Host R&D Day on October 20, 2021
globenewswire.com
2021-10-13 06:45:00CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it will host a virtual R&D Day for analysts and investors at 8:00a.m. ET on Wednesday, October 20, 2021.
No data to display
5 Penny Stocks To Buy According To Analysts, Targets Up To 952%
pennystocks.com
2023-03-07 11:35:38Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
investorplace.com
2023-03-06 10:45:40TCR2 Therapeutics (NASDAQ: TCRR ) stock is jumping more than 30% in early trading on March 6 after the company agreed to merge with Adaptimmune (NASDAQ: ADAP ). Meanwhile, Adaptimmune is falling more than 15%.
TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path
seekingalpha.com
2023-02-15 06:00:01Reprioritization of pipeline sees 40% reduction of workforce with enough cash to fund pipeline into early 2025. Proof of concept established using gavo-cel for the treatment of patients with mesothelin tumors; Focus shift more towards targeting ovarian cancer patients with expected data 2nd half of 2023.
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
globenewswire.com
2023-02-08 06:45:00CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will present a company update at the SVB Securities Global Biopharma Conference (virtual) on Tuesday, February 14, 2023 at 1:00 PM ET.
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
globenewswire.com
2022-11-23 06:45:00CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29 at 2:00PM E.T.
Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)
zacks.com
2022-11-11 11:18:13TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
globenewswire.com
2022-09-27 16:15:00CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T.
TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
globenewswire.com
2022-09-26 16:15:00CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T.
TCR² Therapeutics: Betting On A Solid Reversal
seekingalpha.com
2022-08-18 06:58:46TCR² Therapeutics is a company developing two lead oncology drug candidates targeting mesothelin, a protein expressed on different tumors. Its lead candidate gavo-cel, or TC-210, has presented strong data so far in different solid tumors, including tumor regression in 94% of evaluable patients and a manageable safety profile.
TCR² Therapeutics to Participate in Two Upcoming Conferences in June
globenewswire.com
2022-06-01 06:45:00CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate at two upcoming conferences in June in New York.
TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference
globenewswire.com
2022-02-09 06:45:00CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 at 1:40PM E.T. using a virtual platform.
Here's Why TCR2 Therapeutics Inc. (TCRR) is Poised for a Turnaround After Losing 20.2% in 4 Weeks
zacks.com
2022-01-13 11:33:10TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference
globenewswire.com
2022-01-07 17:00:00CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- https://investors.tcr2.com/
TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference
globenewswire.com
2022-01-05 06:45:00CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Menzel, President and Chief Executive Officer of TCR² Therapeutics, will present an update on Company progress at the H.C. Wainwright BioConnect Conference on Monday, January 10th at 7:00AM E.T. using a virtual platform.
TCRR Stock: Why It Increased Today
pulse2.com
2021-10-20 08:23:47The stock price of TCR2 Therapeutics (Nasdaq: TCRR) increased by over 1% pre-market today. This is why it happened.
TCR² Therapeutics to Host R&D Day on October 20, 2021
globenewswire.com
2021-10-13 06:45:00CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it will host a virtual R&D Day for analysts and investors at 8:00a.m. ET on Wednesday, October 20, 2021.